1 / 5

ISAR-DESIRE 2

ISAR-DESIRE 2. Objective: To assess the efficacy and safety of the PES versus SES for SES restenosis . Study: Multicenter, single blind, randomized trial. Population: Patients with SES restenosis ≥ 50 % in native coronary and signs/symptoms of ischemia. No LM , no AMI.

charissa-reyes
Download Presentation

ISAR-DESIRE 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ISAR-DESIRE 2 Objective: To assess the efficacy and safety of the PES versus SES for SES restenosis. Study: Multicenter, single blind, randomized trial. Population: Patientswith SES restenosis ≥ 50% in native coronary and signs/symptoms of ischemia. No LM, no AMI. Endpoint: In stent late loss.

  2. ISAR-DESIRE 2 SES (Cypher stent) n=225 Plavix ≥ 6months F-up angio 6-8 months n=190 (85%) enrolled ISAR-SES 61% CypherSES 39% n=450 F-up angio 6-8 months n=191 (85%) PES (Taxus stent) n=225

  3. ISAR-DESIRE 2 Late loss in MLD (mm) Binary restenosis at 9 months (%) p=0.85 p=0.85 p=0.69

  4. ISAR-DESIRE 2 Eventrate at 1 year (%) p=0.52 p=0.86 p=0.67 p=0.53

  5. ISAR-DESIRE 2 Conclusion: In cases of SES restenosis treatment with SES and PES was associated with a comparable degree of efficacy and safety. Mehilli et al. J Am CollCardiol 2010;55:2710-6

More Related